ArticleScientific reports2025
Placenta-derived extracellular vesicles in maternal plasma of Hb Bart's fetuses.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- EVennCorona: Annotating Protein Corona of Extracellular Vesicles by Venn Diagram.Journal of extracellular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Hemoglobin (Hb) Bart's disease is the most common cause of hydrops fetalis among Southeast Asians. Given its high fatality rate, prenatal diagnosis and treatment are the key. This condition is associated with placental hypoxia, which can trigger the release of placenta-derived extracellular vesicles (EVs) into the maternal circulation. We aimed to determine the levels of placenta-derived EVs and the proteomic profiles of plasma EVs in women with fetuses with Hb Bart. This prospective cohort study included women with: (1) normal term pregnancies (Group 1; n = 19); (2) Hb Bart's fetuses with hydropic features (Group 2; n = 4); (3) Hb Bart's fetuses without hydrops (Group 3; n = 7); (4) placental associated complications (a disease control group or Group 4; n = 4); and (5) hydrops fetalis from non-Bart's causes (Group 5; n = 5). Maternal plasma EVs were isolated as well as characterized, and their placental alkaline phosphatase (PLAP) content was quantified via ELISA. Proteomic profiles were determined via mass spectrometry. The EVs from the women with fetuses with Hb Bart's with hydrops were smaller than those from the women in the normal and disease control groups. Bart fetuses with hydropic features had higher PLAP levels per EV particle than normal pregnancies. However, PLAP levels per EV seemed to be highest in the patients with placenta-associated complications. Among the 16 differentially expressed EV proteins, hnRNPA2B1 showed the greatest difference between women who had fetuses with Hb Bart's hydrops and those with normal pregnancies or placenta-associated complications. The 16 proteins are involved in aberrant immune responses, pro-inflammatory cytokine regulation, and vascular injuries. These changes may be the result of placental hypoxia associated with Hb Bart's hydrops.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.